In the past week, ZLAB stock has gone up by 5.57%, with a monthly gain of 37.47% and a quarterly surge of 38.66%. The volatility ratio for the week is 5.29%, and the volatility levels for the last 30 days are 5.63% for Zai Lab Limited ADR. The simple moving average for the past 20 days is 13.07% for ZLAB’s stock, with a 58.19% simple moving average for the past 200 days.
Is It Worth Investing in Zai Lab Limited ADR (NASDAQ: ZLAB) Right Now?
The 36-month beta value for ZLAB is also noteworthy at 1.07. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ZLAB is 108.11M, and at present, short sellers hold a 7.24% of that float. The average trading volume of ZLAB on March 14, 2025 was 804.72K shares.
ZLAB) stock’s latest price update
Zai Lab Limited ADR (NASDAQ: ZLAB)’s stock price has gone rise by 6.39 in comparison to its previous close of 36.14, however, the company has experienced a 5.57% increase in its stock price over the last five trading days. businesswire.com reported 2025-03-12 that SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. “In China, cervical cancer is a serious health concern with approximately 150,000 new cases diagnosed annually1,”.
Analysts’ Opinion of ZLAB
Many brokerage firms have already submitted their reports for ZLAB stocks, with Scotiabank repeating the rating for ZLAB by listing it as a “Sector Outperform.” The predicted price for ZLAB in the upcoming period, according to Scotiabank is $55 based on the research report published on March 07, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see ZLAB reach a price target of $36.10, previously predicting the price at $29. The rating they have provided for ZLAB stocks is “Neutral” according to the report published on March 03rd, 2025.
Morgan Stanley gave a rating of “Overweight” to ZLAB, setting the target price at $47.50 in the report published on December 14th of the previous year.
ZLAB Trading at 30.71% from the 50-Day Moving Average
After a stumble in the market that brought ZLAB to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.21% of gains for the given period.
Volatility was left at 5.63%, however, over the last 30 days, the volatility rate increased by 5.29%, as shares surge +32.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.13% upper at present.
During the last 5 trading sessions, ZLAB rose by +4.75%, which changed the moving average for the period of 200-days by +112.89% in comparison to the 20-day moving average, which settled at $33.99. In addition, Zai Lab Limited ADR saw 46.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZLAB starting from Du Ying, who proposed sale 46,389 shares at the price of $35.55 back on Mar 05 ’25. After this action, Du Ying now owns shares of Zai Lab Limited ADR, valued at $1,649,122 using the latest closing price.
GAYNOR RICHARD, the Director of Zai Lab Limited ADR, proposed sale 2,500 shares at $35.07 during a trade that took place back on Mar 05 ’25, which means that GAYNOR RICHARD is holding shares at $87,675 based on the most recent closing price.
Stock Fundamentals for ZLAB
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.63 for the gross margin
The net margin for Zai Lab Limited ADR stands at -0.64. The total capital return value is set at -0.32. Equity return is now at value -31.41, with -23.14 for asset returns.
Based on Zai Lab Limited ADR (ZLAB), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -125.16.
Currently, EBITDA for the company is -242.99 million with net debt to EBITDA at 1.22. When we switch over and look at the enterprise to sales, we see a ratio of 9.53. The receivables turnover for the company is 4.46for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.51.
Conclusion
In summary, Zai Lab Limited ADR (ZLAB) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
